Examples include volasertib (NCT02003573), a polo-like kinase 1 (PLK-1) inhibitor recently designated an “orphan drug” for AML [27], the first-in-class neddylation inhibitor MLN4924 (NCT01814826), the hedgehog inhibitor sonidegib (NCT02129101) and the Bcl-2-selective antagonist, ABT-199 (NCT02203773). This evidence concerns the gene BCL2 and acute myeloid leukemia.